India’s Dearth of Drug R&D Investment Creates Innovation Bottleneck
This article was originally published in PharmAsia News
BOSTON - India faces a lacuna in research and development funding, with lags in government investment and venture capital activity that are creating roadblocks to accelerating the country's growth in the pharmaceutical sector, experts said at the USA-India Chamber of Commerce BioPharma & Healthcare Summit in Boston
You may also be interested in...
SINGAPORE - There is no dearth of research programs - the trouble is capital has evaporated and risk appetite is anorexic, BioMedical Asia speakers said in Singapore March 17
Network Group BayHelix Links Life Sciences Leaders To Blaze New Trail In China – An Interview With PharmAsia News (Part 2 of 2)
BayHelix is a non-profit, invitation-only organization for ethnic Chinese leaders in the global life sciences arena. Created in the San Francisco Bay Area in 2001, BayHelix has since become a bridge linking 300-plus Chinese business, law and science professionals in the health care industry across the U.S., Canada and Greater China. Recently the chairman of BayHelix, James Zhu, managing partner of Perkins Coie's Beijing Office, and the group's two co-founders, Jonathan Wang, OrbiMed's managing director in Asia, and Steve Yang, vice president, Head of Asia R&D at Pfizer, sat down with PharmAsia News' Shanghai Bureau to talk about the founding and the future of BayHelix as well as the challenges and opportunities in China's life sciences sector.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).